⌘K
t
Tissue Regenix Group plc announced it received notification for the exercise of options to subscribe for 2,717,391 new ordinary shares at an exercise price of 0.1 pence per share. An application has been made for these new shares to be admitted to AIM trading, with admission expected at 8:00 a.m. on 21 June 2022. Following this issue, the Company's total voting rights will comprise 7,035,794,890 ordinary shares.
| Date | 16 Jun 2022 |
| Time | 13:27:00 |
| Category | Capital structure |
| ID | 1806P |
Tissue Regenix Group plc
("Tissue Regenix", the "Company" or "the Group")
Exercise of Options
And Total Voting Rights
Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that it has received notification for the exercise of options to subscribe for 2,717,391 new ordinary shares in the Company ("Ordinary Shares") at an exercise price of 0.1 pence per Ordinary Share.
The 2,717,391 new Ordinary Shares will rank pari passu with the existing Ordinary Shares and application has been made for these new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will occur at 8:00 a.m. on 21 June 2022.
Total Voting Rights
Following the issue of the 2,717,391 new Ordinary Shares, the Company will have a total of 7,035,794,890 Ordinary Shares in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For more information:
|
Tissue Regenix Group plc |
||
|
David Cocke, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) |
Tel: +44(0)20 7710 7600 |
|
|
Ben Maddison / Nick Harland |
|
|
|
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 |
|
|
Alice Woodings / Lianne Applegarth |
TissueRegenix@walbrookpr.com |
|
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.